NSF award 2546548 · University of Colorado at Boulder

Regulation of RNA polymerase II transcription at gene 3-ends by CDK7 kinase

Final report due

28 September 2030

in 1,441 days · The award ends on 31 May 2030.

GrantClerk is a private service. We are not NSF or any government agency.

Dates this award owes

NSF emails you about this too.

Decide about an extension31 Jan 2030in 1201 days
award ending 2030-05-31 · Research.gov
This one is ours, not NSF’s.
Extension request16 Apr 2030in 1276 days
award ending 2030-05-31 · Research.gov
PAPPG 24-1: “at least 45 days prior to the end date”
No-cost extension notice21 May 2030in 1311 days
award ending 2030-05-31 · Research.gov
PAPPG 24-1: “at least ten calendar days prior to the end date”
Final report due28 Sep 2030in 1441 days
award ending 2030-05-31 · Research.gov
PAPPG 24-1: “no later than 120-days following the end date of the award”
Project outcomes report due28 Sep 2030in 1441 days
award ending 2030-05-31 · Research.gov
PAPPG 24-1: “no later than 120 days following the end date”
Award is closed out28 Sep 2030in 1441 days
award ending 2030-05-31 · Research.gov
PAPPG 24-1: “financially closed out 120 days after their expiration date”

Annual report dates come from the budget period on your award notice. That date is not public, so it is not shown here.

How we got this date

NSF lists this award's end date as 31 May 2030.
NSF rules say the final report is due no later than 120 days after that.
So the final report is due by 28 September 2030.

Read the rule on Research.gov

Get a note before each report date

Add this award to your desk. We email you before each date and keep the dates in one place.

Renews each year until you cancel. Cancel any time from your account.

Already a member? Sign in

Award card

Award number: 2546548
Period of support: 15 Jun 2026 – 31 May 2030
Amount: $1,493,073
Awardee: University of Colorado at Boulder, Boulder, CO
Program: Molecular Biosciences
Directorate: BIO

Abstract

This collaborative project focuses on an enzyme called CDK7, which is critical for all physiological processes (e.g., human development, growth, maintenance of normal cell function). Aberrant CDK7 activity contributes to developmental disorders and cancer; thus, understanding how CDK7 works has broad health implications and will advance molecular therapeutics. CDK7 controls how the human genome is decoded by RNA…

Is this right?

We copy this from the public NSF award record. Your award notice and NSF always win. If a date looks wrong, check Research.gov.